My ePortfolio Register   

IMPAKT 2017 /
Genetic determinants of breast cancer immune phenotypes

4th - 6th May 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 397
Rating:

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Dr Curigliano speaks with ecancer at IMPAKT 2017 about predicting patient response to checkpoint immunotherapy through genetic screening.

He introduces a patient subpopulation with an overexpression of Immunologic Constant of Rejection (ICR) within HER2 /triple negative breast cancer who are most responsive to immunotherapy.

Dr Curigliano highlights that these tumour subtypes are also most often associated with tumour infiltration by lymphocytes, and that this stratification of response could help in selecting treatments for patients.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence